Sorafenib for recurrent hepatocellular carcinoma after liver transplantation: a South American experience
Fuente:
Redalyc
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artículo científico |
| Lingua: | en |
| Pubblicazione: |
Sociedad Argentina de Gastroenterología
2016
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1876480694837837824 |
|---|---|
| author | Federico Piñero |
| author_facet | Federico Piñero |
| contents | Sorafenib for recurrent hepatocellular carcinoma after liver transplantation: a South American experience Federico Piñero Sebastián Marciano Margarita Anders Federico Orozco Ganem Alina Zerega Josemaría Menéndez Manuel Mendizábal Matías Tisi Baña Octavio Gil Solange Gerona Eduardo de Santibañes Ricardo Mastai Adrián Gadano Marcelo Silva Medicina Liver cancer therapeutics transplantation Recurrent hepatocellular carcinoma (HCC) after liver trans plantation (LT) has been related with dismal prognosis. The aim of this study was to describe the treatments performed after HCC recurrence in 2 LatinAmerican countries, and to identify significant factors related to post progression sur vival. Methods. From 803 adult transplanted patients in 5 LT centers from Argentina and Uruguay (20052011), patients with HCC recurrence were included. “Early recur rence” was considered when it occurred during the first year after transplantation. Patients were analyzed according to the treatment introduced after recurrence diagnosis. The post pro gression survival was compared. Results. Recurrence presented in 20 out of 135 patients (14.8%), 11 (55%) had early re currences. After recurrence, 14 patients had good performance status and 18 were Child Pugh A. Ten patients received best supportive care (BSC), 10 patients sorafenib, 1 patient local radiotherapy and 1 patient loco regional surgery. Patients with sorafenib had prolonged post progression survival compared to BSC (5.0 months vs 3.0 months; p = 0.04). On multivari ate Cox regression analysis, early recurrence was the only factor related to worst survival, hazard ratio = 3.8 (p = 0.01). A survival benefit with sorafenib in patients with late recurrence when compared to early recurrence was observed (16.0 vs 3.0 months, respectively; p = 0.027). Conclusion. although effi cacy of Sorafenib for recurrent HCC should be evaluated in a muchneeded randomized controlled trial, a timeselection criterion for this treatment should also be assessed. 2016 artículo científico 2469-1119 https://www.redalyc.org/articulo.oa?id=199349172003 en http://www.redalyc.org/revista.oa?id=1993 Acta Gastroenterológica Latinoamericana application/pdf Sociedad Argentina de Gastroenterología Acta Gastroenterológica Latinoamericana (Argentina) Num.4 Vol.46 |
| format | Artículo científico |
| id | redalyc_199349172003 |
| institution | Redalyc |
| language | en |
| publishDate | 2016 |
| publisher | Sociedad Argentina de Gastroenterología |
| spellingShingle | Sorafenib for recurrent hepatocellular carcinoma after liver transplantation: a South American experience Federico Piñero Medicina Liver cancer therapeutics transplantation Sorafenib for recurrent hepatocellular carcinoma after liver transplantation: a South American experience Federico Piñero Sebastián Marciano Margarita Anders Federico Orozco Ganem Alina Zerega Josemaría Menéndez Manuel Mendizábal Matías Tisi Baña Octavio Gil Solange Gerona Eduardo de Santibañes Ricardo Mastai Adrián Gadano Marcelo Silva Medicina Liver cancer therapeutics transplantation Recurrent hepatocellular carcinoma (HCC) after liver trans plantation (LT) has been related with dismal prognosis. The aim of this study was to describe the treatments performed after HCC recurrence in 2 LatinAmerican countries, and to identify significant factors related to post progression sur vival. Methods. From 803 adult transplanted patients in 5 LT centers from Argentina and Uruguay (20052011), patients with HCC recurrence were included. “Early recur rence” was considered when it occurred during the first year after transplantation. Patients were analyzed according to the treatment introduced after recurrence diagnosis. The post pro gression survival was compared. Results. Recurrence presented in 20 out of 135 patients (14.8%), 11 (55%) had early re currences. After recurrence, 14 patients had good performance status and 18 were Child Pugh A. Ten patients received best supportive care (BSC), 10 patients sorafenib, 1 patient local radiotherapy and 1 patient loco regional surgery. Patients with sorafenib had prolonged post progression survival compared to BSC (5.0 months vs 3.0 months; p = 0.04). On multivari ate Cox regression analysis, early recurrence was the only factor related to worst survival, hazard ratio = 3.8 (p = 0.01). A survival benefit with sorafenib in patients with late recurrence when compared to early recurrence was observed (16.0 vs 3.0 months, respectively; p = 0.027). Conclusion. although effi cacy of Sorafenib for recurrent HCC should be evaluated in a muchneeded randomized controlled trial, a timeselection criterion for this treatment should also be assessed. 2016 artículo científico 2469-1119 https://www.redalyc.org/articulo.oa?id=199349172003 en http://www.redalyc.org/revista.oa?id=1993 Acta Gastroenterológica Latinoamericana application/pdf Sociedad Argentina de Gastroenterología Acta Gastroenterológica Latinoamericana (Argentina) Num.4 Vol.46 |
| title | Sorafenib for recurrent hepatocellular carcinoma after liver transplantation: a South American experience |
| topic | Medicina Liver cancer therapeutics transplantation |
| url | https://www.redalyc.org/articulo.oa?id=199349172003 |